Fifty‐six percent of patients had a recognized degree of disability (68% of LCHAD deficiency patients, 67% of MTP deficiency patients, 50% of CPT2 deficiency patients, 40% of VLCAD deficiency patients) and 36% had a care degree (56% of MTP deficiency patients, 44% of LCHAD deficiency patients, 24% of VLCAD deficiency patients). The gene discussed is CPT2; the disease is very long chain acyl-CoA dehydrogenase deficiency.